| Name | E3330 |
| Description | E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity. |
| Cell Research | PANC1 cells are placed in one well of a 12-well plate and treated with 5 to 30 μM E3330. After a 24, 48, and 72 h of culture, the cells are washed with PBS and stained with trypan blue, and cell viability is examined by counting the live cell numbers.(Only for Reference) |
| In vitro | E3330 affects hemangioblast development in vitro via inhibition of Ape1 redox activity. [1] E3330 inhibits the growth of human pancreatic cancer cell line PANC1, XPA1, MIAPACA, BxPC3, and PK9. E3330 also promotes exit of cell cycle in PANC1 cells, inhibits the DNA-Binding activity of HIF-1α and migration of pancreatic cancer cells. [2] In JHH6 cells, E3330 prevents the functional activation of NF-κB via the alteration of APE1 subcellular trafficking and reduces IL-6 and IL-8 expression induced by TNF-α and FAs accumulation through blockage of the redox-mediated activation of NF-κB. [3] |
| In vivo | In mice with endotoxin-mediated hepatitis, E3330 (300 mg/kg, p.o.) attenuates the elevation of plasma tumor necrosis factor activity and protectes mice from liver injury. [4] In Rat model, E3330 (100 mg/kg, p.o.) also protectes rats from severe liver injury induced with endotoxin plus galactosamine. [5] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.28 mM), Sonication is recommended.
DMSO : 50 mg/mL (132.11 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 70 mg/mL (184.96 mM), Sonication is recommended.
|
| Keywords | VEGFR | Vascular endothelial growth factor receptor | TNF-α | RNASynthesis | RNA Synthesis | REF-1 | Reactive Oxygen Species | PCECs | pancreatic cancer | PANC1 | orally | Nuclear factor-κB | Nuclear factor-kappaB | NSCLC cells | NF-κB | neuroprotective | Inhibitor | inhibit | IL-8 | Hypoxia-inducible factors | HUVECs | HIFs | HIFProlylHydroxylase | HIF-PH | HIF/HIFProlylHydroxylase | HIF/HIF Prolyl-Hydroxylase | HIF/HIF ProlylHydroxylase | HIF Prolyl-Hydroxylase | HIF ProlylHydroxylase | HIF | H1975 | EPCs | endonuclease | E-3330 | E3330 | E 3330 | DNASynthesis | DNA-binding | DNA/RNA Synthesis | DNA Synthesis | APX-3330 | APX3330 | APX 3330 | APE1(Ref-1) | APE1 | AP-1 | anticancer | Activator Protein 1 |
| Inhibitors Related | Ethoxyquin | Kaolin | Allopurinol | Cysteamine hydrochloride | Kojic acid | Guanidine hydrochloride | 1,4-Naphthoquinone | Ethyl linoleate | Hydroxycitric acid tripotassium hydrate | L-Cystine | Thymidine | Dimethyl phthalate |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Hematonosis Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
